Arrowhead price target raised to $80 from $60 at H.C. Wainwright
H.C. Wainwright analyst Patrick Trucchio raised the firm’s price target on Arrowhead (ARWR) to $80 from $60 and keeps a Buy rating on the ...
Arrowhead requests regulatory clearance to initiate ARO-ALK7 trial
Arrowhead (ARWR) announced that it has filed a request for regulatory clearance to initiate a Phase 1/2a clinical trial of ARO-ALK7, the ...
ARWR: License and Collaboration Deal with Sarepta Includes $825 Million Upon Closing…
ARWR READ THE FULL ARWR RESEARCH REPORT Business Update Collaboration Deal with Sarepta Includes $825 Million Upon Closing On November 26, 2024, Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) announced ...